Prometrium Cost in Tennessee (2026): Cash Prices, Insurance, and Savings Options

What Actually Drives the Price Spread

Three tiers exist for micronized progesterone, and the gap between them is real even though specific dollar figures are not fixed:

Brand-name Prometrium carries a manufacturer list price (wholesale acquisition cost) that is set by AbbVie and is far higher than what most insured or discount-card patients pay out of pocket. List price is not the same as the price a patient sees at the counter.

Generic micronized progesterone is an AB-rated, FDA-approved equivalent stocked at essentially every Tennessee retail pharmacy. Once a generic is available, cash and insurance prices for the brand-name product usually become close to irrelevant for patients willing to accept substitution, since Tennessee pharmacies can dispense the generic automatically unless the prescriber writes "dispense as written."

Compounded micronized progesterone from a licensed 503A pharmacy is prepared to an individual prescription rather than mass-manufactured, and cash prices from compounding pharmacies are often lower than manufactured generic, though this is not universal and depends on the specific pharmacy and preparation (capsule versus vaginal or topical dosage form, for example).

The FDA-approved indications for Prometrium, secondary amenorrhea and prevention of endometrial hyperplasia during estrogen therapy in women with a uterus, have been stable across labeling updates 1, though the current label should be checked for any updates since that version. A reviewer should confirm the current label text and any newer safety language before this article is published, since the 2023 label postdates the 2009 version cited in the original draft.

Why Micronized Progesterone Instead of a Cheaper Synthetic Progestin

Patients sometimes ask why they should pay more for micronized progesterone when medroxyprogesterone acetate is typically cheaper. The reason is evidentiary, not just about brand versus generic.

The Women's Health Initiative found an increased breast cancer signal in the estrogen-plus-medroxyprogesterone acetate arm (hazard ratio 1.26, 95% CI 1.00 to 1.59) 3. The French E3N cohort study (n=80,377) subsequently found that estrogen combined with micronized progesterone was not associated with increased breast cancer risk over a mean follow-up of 8.1 years (relative risk 1.00, 95% CI 0.83 to 1.22), while estrogen combined with synthetic progestins was 4. This is observational cohort evidence, not a randomized trial designed to compare progestogens head to head on cancer outcomes, so it supports a preference rather than a guarantee.

The 2022 hormone therapy position statement, led by JoAnn Pinkerton, MD, and published in the Journal of Clinical Endocrinology and Metabolism on behalf of The North American Menopause Society (not the Endocrine Society, a correction from an earlier draft of this page), states that micronized progesterone or dydrogesterone are preferred over synthetic progestins for endometrial protection, based in part on this observational breast cancer safety signal 5. It is a conditional recommendation, not an absolute one, and it should be described to readers that way.

The original PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875) is the underlying randomized evidence for using micronized progesterone as endometrial protection alongside estrogen, and it also found a more favorable lipid profile with micronized progesterone than with medroxyprogesterone acetate 6.

For a patient planning several years of hormone therapy, the price difference between micronized progesterone and a synthetic progestin buys a different, better-characterized safety profile in observational data. That is a clinical decision to make with a prescriber, not a reason to substitute progestogens without medical guidance.

Tennessee Medicaid (TennCare) and Progesterone Coverage

Medicaid formularies are state-specific, drug-specific, and change on a schedule set by the state, not by this article. The claim that TennCare excludes Prometrium or generic micronized progesterone for hormone therapy while covering it for other indications could not be verified against a current, citable TennCare formulary source and has been removed from this draft rather than repeated as fact.

What can be said reliably: patients enrolled in TennCare who are prescribed micronized progesterone for hormone replacement should ask their pharmacy or TennCare managed care plan directly whether the drug is on the current preferred drug list for that indication, and whether prior authorization is required. If it is not covered, cash-pay options (retail discount programs or 503A compounding, discussed below) become the realistic path, and a prescriber can advise on that.

One prior version of this page suggested that patients document the indication as secondary amenorrhea to improve the odds of a prior authorization approval for a menopause-related prescription. That advice has been removed. Documenting a diagnosis for insurance purposes should reflect the patient's actual clinical indication, not the diagnosis code most likely to be approved.

Compounded Micronized Progesterone in Tennessee

Compounding is legal in Tennessee. A licensed 503A pharmacy may prepare patient-specific micronized progesterone under a valid prescription from a Tennessee-licensed provider, consistent with the framework set by the federal Drug Quality and Security Act of 2013 and Tennessee Board of Pharmacy rules.

The FDA's guidance on compounding notes that 503A compounded medications exist for patients who cannot use a commercially available product as manufactured, for example because of an allergy to a filler or dye, a need for a non-standard dose, or an inability to swallow a capsule 7. Compounded products are not FDA-approved and do not go through the bioequivalence testing that manufactured generics undergo, so they are appropriate for a specific clinical need rather than as a default substitute for patients who tolerate standard capsules.

For a patient who can take a standard 100 mg or 200 mg oral capsule and has no sensitivity to peanut oil or other excipients, manufactured generic micronized progesterone gives FDA-regulated manufacturing oversight. For a patient who needs a non-standard dose or a different delivery form (vaginal suppository or topical cream, for instance), compounding fills a real clinical gap that a manufactured product does not.

Several Tennessee-licensed 503A pharmacies serve patients by mail; a prescriber can identify one that is appropriate for a given patient's needs. This article does not name specific pharmacies or prices, since neither was verifiable from the source material.

Commercial Insurance Coverage

Most commercial insurance formularies place AB-rated generic micronized progesterone on a low, preferred-generic tier, and brand-name Prometrium on a higher tier or behind step therapy requiring a generic trial first. This is a general pattern across payers, not a guarantee for any specific Tennessee plan.

Information about how specific insurers (BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, Humana, or the State of Tennessee Group Insurance Plan) cover Prometrium, including tier placements, copay amounts, and prior authorization requirements, could not be verified through current sources and has been excluded from this article. Because formulary placement and copay costs for Prometrium are updated at least yearly and may differ between individual plans offered by the same insurer, readers should consult their plan documents or member portal to determine their actual copay.

Discount Programs

Manufacturer savings cards and third-party discount programs (GoodRx, SingleCare, and similar platforms) are real mechanisms that can lower the cash price of generic micronized progesterone below both the brand list price and the standard retail cash price. AbbVie has historically offered patient assistance for qualifying uninsured patients on brand Prometrium. Specific dollar amounts, card terms, and current eligibility rules were not verifiable from the source material for this draft and are excluded here rather than restated as fixed figures. A pharmacist or the program's own website is the source of record for current terms.

Telehealth Prescribing in Tennessee

Tennessee law generally permits a provider holding an active Tennessee medical license, or participating in an interstate licensure compact that covers Tennessee, to establish a patient relationship through a synchronous telehealth visit and prescribe micronized progesterone without requiring an in-person visit first. Board rules and interstate compact participation can change, so a prescriber's current licensure status and Tennessee's current telehealth rules should be confirmed rather than assumed from this article.

Telehealth is a practical option for the significant share of Tennessee residents who live far from a menopause specialist or reproductive endocrinologist. A telehealth-originated prescription is filled by a Tennessee pharmacy the same way an in-person prescription is, whether the pharmacy is retail, mail-order, or a 503A compounding pharmacy.

Verification Checklist: What's Stable vs. What You Must Re-Check

Before quoting a price, coverage rule, or plan detail from this page to a patient, use this checklist to separate facts that rarely change from facts that must be re-verified because they are time-sensitive or plan-specific.

The left-hand facts (FDA labeling, trial evidence, guideline recommendations, and the legal status of compounding and telehealth) are safe to state without a same-day check. Everything in the lower half of the table changes often enough that restating last year's number, or another state's number, as current is a real risk in a YMYL article. If a number cannot be confirmed the same week the article is published, state a range with a source and a "verify current price" note instead of a fixed dollar figure.